Kato K (2019) and Kojima T (2020) independently reported clinical trial outcomes demonstrating the efficacy of anti-PD-1 antibodies (e.g., nivolumab) in patients with advanced esophageal cancer (11, 31), thereby validating the clinical feasibility of immunotherapeutic approaches. This evidence concerns the gene PDCD1 and esophageal cancer.